DLX5

Across TCGA pan-cancer cohorts, DLX5 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of DLX5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where DLX5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DLX5 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

HNSC, KIRC, and LUSC are the cancer types where DLX5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DLX5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+2.913	<.001	12	view →
KIRC	Female	III,IV	+1.622	<.001	12	view →
LUSC	Female	II,III,IV	+4.017	<.001	8	view →
LUAD	All	All	+0.876	<.001	7	view →
LIHC	All	II,III,IV	+0.619	<.001	7	view →
UCEC	All	II,III,IV	+5.576	<.001	6	view →
BRCA	Female	All	+0.764	<.001	6	view →
COAD	All	All	+0.201	.011	5	view →
READ	Male	All	+0.866	.005	4	view →
BLCA	All	All	+1.303	.012	3	view →
PAAD	Male	All	−1.039	.032	2	view →
THCA	All	All	+0.361	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

DLX5–HNSC

Open the HNSC breakdown →